These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
274 related articles for article (PubMed ID: 5019377)
41. Clinical evaluation of amantadine therapy for parkinsonism and the side effects--in cases of thalamic surgery and L-dopa therapy. Matsumoto K; Omoto T; Beck H Folia Psychiatr Neurol Jpn; 1974 Jan; 28(1):1-10. PubMed ID: 4406943 [No Abstract] [Full Text] [Related]
42. [The therapeutic effectiveness of amantadine (midantan) in parkinsonism syndromes]. Kiseleva AM; Zlydnikov DM; Mazhinskaia VP; Lebedeva VK; Zakharova NG Zh Nevropatol Psikhiatr Im S S Korsakova; 1973; 73(4):530-4. PubMed ID: 4705408 [No Abstract] [Full Text] [Related]
43. [Amantadine in Parkinson's disease]. Vecchi L Clin Ter; 1971 Jun; 57(5):471-5. PubMed ID: 5113576 [No Abstract] [Full Text] [Related]
44. [Clinical considerations on therapy of parkinsonian syndromes with amantadine and L-Dopa]. Ambrosetto C; Martinelli P Minerva Med; 1971 Oct; 62(82):4017-9. PubMed ID: 5125069 [No Abstract] [Full Text] [Related]
45. [Treatment of Parkinson's syndrome with L-dopa associated with diphenhydramine hydrochloride and amantadine hydrochloride]. Scotti G Sist Nerv; 1970; 22(2):144-52. PubMed ID: 5504553 [No Abstract] [Full Text] [Related]
50. Amantadine in Parkinson's disease. Review of more than two years' experience. Schwab RS; Poskanzer DC; England AC; Young RR JAMA; 1972 Nov; 222(7):792-5. PubMed ID: 4677928 [No Abstract] [Full Text] [Related]
51. The effect of adding amantadine to optimum L-dopa dosage in Parkinson's syndrome. Fehling C Acta Neurol Scand; 1973; 49(2):245-51. PubMed ID: 4577929 [No Abstract] [Full Text] [Related]
52. Combined treatment in Parkinson's disease. Wheatley D Practitioner; 1983 Mar; 227(1377):446-7. PubMed ID: 6889232 [No Abstract] [Full Text] [Related]
53. Double blind study using amantadine hydrochloride in the therapy of Parkinson's disease. Silver DE; Sahs AL Trans Am Neurol Assoc; 1971; 96():307-8. PubMed ID: 4945919 [No Abstract] [Full Text] [Related]
54. [The addition of amantadine to prolonged treatment with L-Dopa. Considerations on 20 cases]. Giuffrè R; Gambacorta D Minerva Med; 1971 Oct; 62(82):4009-12. PubMed ID: 5125066 [No Abstract] [Full Text] [Related]
56. [Amantadine and dexetimide in the treatment of parkinsonism]. Hakkarainen H; Viukari M Duodecim; 1973 Jul; 89(21):1437-41. PubMed ID: 4586970 [No Abstract] [Full Text] [Related]
57. The treatment of parkinsonism with L-Dopa and amantadine. Green J J Fla Med Assoc; 1970 Jun; 57(6):28-33. PubMed ID: 5445813 [No Abstract] [Full Text] [Related]
58. [Preliminary results of the use of amantadine in parkinsonian syndromes]. Montanari M; Monaco V; Robotti CA Minerva Med; 1971 Oct; 62(82):3955-7. PubMed ID: 5125050 [No Abstract] [Full Text] [Related]
59. The management of parkinsonism. N Z Med J; 1971 Jul; 74(470):36-7. PubMed ID: 5289750 [No Abstract] [Full Text] [Related]
60. Plasma amantadine concentrations in patients with Parkinson's disease. Nishikawa N; Nagai M; Moritoyo T; Yabe H; Nomoto M Parkinsonism Relat Disord; 2009 Jun; 15(5):351-3. PubMed ID: 18823813 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]